Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?

about

The Effects of CYP2C19 genotype on the susceptibility for nephrosis in cardio-cerebral vascular disease treated by anticoagulation

P2860

Q37300683-0928AE9D-76B9-4284-8E74-1A95300AEA2B

P2860

Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?

Item

http://www.wikidata.org/entity/Q38619150

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Clopidogrel, prasugrel, ticagr ...... pairment: do we have a winner?

@en

type

Item

label

Clopidogrel, prasugrel, ticagr ...... pairment: do we have a winner?

@en

prefLabel

Clopidogrel, prasugrel, ticagr ...... pairment: do we have a winner?

@en

P1476

Clopidogrel, prasugrel, ticagr ...... pairment: do we have a winner?

@en

P2093

Ales Tomek

http://www.w3.org/2001/XMLSchema#string

Alex N Pokov

http://www.w3.org/2001/XMLSchema#string

Moo Hyun Kim

http://www.w3.org/2001/XMLSchema#string

Victor L Serebruany

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Vorapaxar in the secondary prevention of atherothrombotic events.

Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study

P304

1333-1344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14779072.2015.1101343

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26513059

http://www.w3.org/2001/XMLSchema#string

P921

clopidogrel

Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?

about

P2860

P2860

Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921